← All trials
NCT04031677
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2020
- Primary completion
- Apr 21, 2027
- Completion date
- Apr 21, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- University of MilanStudy chair
- Netherlands Cancer InstituteStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.